. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2018 Oct 18;25(3):577–586. doi: 10.1016/j.bbmt.2018.10.011

Table 3.

Cumulative incidence of CMV infection and competing-risk events.

	100-day CInc of CMV infection, including steroids as CR	p-value	100-day CInc of CMV infection, excluding steroids as CR	p-value
Entire At-risk Cohort	30% (24–35%)		47% (40–52%)
D/R Serostatus		<0.0001		<0.0001
−/−	2% (0–7%)		4% (0–9%)
−/+	33% (22–44%)		52% (40–63%)
+/−	9% (2–21%)		12% (4–25%)
+/+	33% (26–40%)		53% (45–60%)
Graft Source		p=0.001		p=0.0001
Marrow	33% (20–46%)		54% (39–67%)
PBSC	26% (20–33%)		43% (36–49%)
UCB	65% (34–84%)		82% (51–95%)
T-cell Manipulation Strategy		0.007		NS
PTCy-based	26% (14–40%)		49% (32–63%)
Serotherapy	36% (24–49%)		44% (30–56%)
TCD	47% (28–64%)		60% (40–75%)
CNI/mTORi-based	19% (13–27%)		40% (31–49%)
Graft T-cell Dose		NS		NS
<1 × 10⁶ CD3/kg	41% (23–57%)		56% (37–72%)
1–9.9 × 10⁶ CD3/kg	33% (11–58%)		53% (25–75%)
1–9.9 × 10⁷ CD3/kg	33% (23–43%)		52% (40–62%)
1–9.9 × 10⁸ CD3/kg	24% (17–31%)		40% (32–49%)

Abbreviations: CMV, cytomegalovirus; D/R, donor/recipient; PBSC, peripheral blood stem cell; UCB, umbilical cord blood; PTCy, post-transplantation cyclophosphamide; TCD, ex vivo T-cell depletion; CNI, calcineurin inhibitor; mTORi, mammalian target of rapamycin inhibitor; CInc, cumulative incidence; CR, competing risk